Identification of E2F-1/Cyclin A antagonists
Authors:
- Sushil K. SharmaSSSushil K. Sharma
- Timothy M. RamseyTRTimothy M. Ramsey
- Ying-Nan P. ChenYCYing-Nan P. Chen
- Weichun ChenWCWeichun Chen
- Mary S. MartinMMMary S. Martin
- Kenneth CluneKCKenneth Clune
- Michael SabioMSMichael Sabio
- Kenneth W. BairKBKenneth W. Bair
- 1 September 2001
- journal article
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 11 (18) , 2449-2452
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- Overexpression of E2F‐1 in glioma triggers apoptosis and suppresses tumor growth in vitro and in vivoNature Medicine, 1998
- Role of the retinoblastoma protein in the pathogenesis of human cancer.Journal of Clinical Oncology, 1997
- Tumor-selective transgene expression in vivo mediated by an E2F-responsive adenoviral vectorNature Medicine, 1997
- Cancer Cell CyclesScience, 1996
- Unrestricted cell cycling and cancerNature Medicine, 1995
- Cyclin A-kinase regulation of E2F-1 DNA binding function underlies suppression of an S phase checkpointCell, 1995
- Deregulated expression of E2F-1 induces S-phase entry and leads to apoptosis.Molecular and Cellular Biology, 1994
- Deregulated transcription factor E2F-1 expression leads to S-phase entry and p53-mediated apoptosis.Proceedings of the National Academy of Sciences, 1994
- p53 and E2F-1 cooperate to mediate apoptosis.Proceedings of the National Academy of Sciences, 1994
- Expression of transcription factor E2F1 induces quiescent cells to enter S phaseNature, 1993